Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.20.4
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Operating expenses:    
Research and development $ 18,135,862 $ 9,739,000
General and administrative 40,954,253 24,811,000
Depreciation and amortization 94,000 54,000
Total operating expenses 59,183,648 34,604,000
Loss from operations (59,184,000) (34,604,000)
Other income (expense):    
Interest income, net 45,000 133,000
Loss on foreign currency translation (1,000) 0
Loss before income taxes (59,140,000) (34,471,000)
Income taxes (benefit) 0 0
Net loss (59,140,000) (34,471,000)
Non-controlling interest 6,921,709 415,849
Net loss attributable to BioSig Technologies, Inc. (52,218,000) (34,055,000)
Preferred stock dividend (14,000) (25,000)
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS $ (52,232,000) $ (34,080,000)
Net loss per common share, basic and diluted (in Dollars per share) $ (1.87) $ (1.65)
Weighted average number of common shares outstanding, basic and diluted (in Shares) 27,906,584 20,694,662